Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carboplatin + etoposide + atezolizumab in previously untreated elderly patients with advanced small cell lung cancer
jRCT1061200024Phase 2Recruiting
- Start
- Dec 2020
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carboplatin, etoposide and atezolizumab in small cell lung cancer (SCLC). Primary endpoint: 1-year survival rate. Started Dec 2020; status: recruiting.
02
Drugs
carboplatinetoposideatezolizumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on jRCT1061200024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1061200024.